早期诊断和治疗对于改善软骨发育不全患儿身高结局的意义和思考

李黎; 熊丰

doi:10.7499/j.issn.1008-8830.2410107

PDF(620 KB)

HTML

中国当代儿科杂志 ›› 2025, Vol. 27 ›› Issue (3) : 262-268. DOI: 10.7499/j.issn.1008-8830.2410107

系列述评——生长障碍疾病诊疗

早期诊断和治疗对于改善软骨发育不全患儿身高结局的意义和思考

李黎^1,2, 熊丰¹

作者信息 +

Significance and considerations of early diagnosis and treatment for improving height outcomes in children with achondroplasia

LI Li, XIONG Feng

Author information +

文章历史 +

摘要

软骨发育不全（achondroplasia, ACH）是儿科临床常见的骨骼发育不良性疾病，其主要致病基因为成纤维细胞生长因子受体3（fibroblast growth factor receptor 3, FGFR3）基因。该基因突变导致四肢长骨、椎骨等骨骼的软骨内成骨过程受损，患儿通常表现为身材矮小，并伴有严重的多系统并发症。ACH的诊断主要依据典型的临床表现、影像学特征和基因检测结果。治疗方面，主要通过药物和外科手术解决身高问题，并对症处理各类并发症。为进一步加深对ACH疾病的认识，该文对ACH的产前诊断、临床诊断以及针对身高问题的治疗方案进行了系统分析与阐述。

Abstract

Achondroplasia (ACH) is a common skeletal dysplasia in children, primarily caused by mutations in the fibroblast growth factor receptor 3 (FGFR3) gene. These mutations disrupt the process of endochondral ossification in different types of bones, including long bones of the limbs and vertebrae. Children with ACH typically present with short stature and may experience severe multi-system complications. The diagnosis of ACH is based on typical clinical manifestations, imaging features, and genetic testing results. Treatment options mainly include pharmacological interventions and surgical procedures aimed at improving height, as well as symptomatic management for associated complications. This article discusses both prenatal and clinical diagnostic approaches for ACH, as well as treatment strategies focused on enhancing height, aiming to deepen the understanding of this condition.

导出引用

李黎, 熊丰. 早期诊断和治疗对于改善软骨发育不全患儿身高结局的意义和思考[J]. 中国当代儿科杂志. 2025, 27(3): 262-268 https://doi.org/10.7499/j.issn.1008-8830.2410107

LI Li, XIONG Feng. Significance and considerations of early diagnosis and treatment for improving height outcomes in children with achondroplasia[J]. Chinese Journal of Contemporary Pediatrics. 2025, 27(3): 262-268 https://doi.org/10.7499/j.issn.1008-8830.2410107

参考文献

1 Foreman PK, van Kessel F, van Hoorn R, et al. Birth prevalence of achondroplasia: a systematic literature review and meta-analysis[J]. Am J Med Genet A, 2020, 182(10): 2297-2316. PMID: 32803853. PMCID: PMC7540685. DOI: 10.1002/ajmg.a.61787.
2 Savarirayan R, Ireland P, Irving M, et al. International consensus statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia[J]. Nat Rev Endocrinol, 2022, 18(3): 173-189. PMID: 34837063. DOI: 10.1038/s41574-021-00595-x.
3 Pauli RM. Achondroplasia: a comprehensive clinical review[J]. Orphanet J Rare Dis, 2019, 14(1): 1. PMID: 30606190. PMCID: PMC6318916. DOI: 10.1186/s13023-018-0972-6.
4 Kim HY, Ko JM. Clinical management and emerging therapies of FGFR3-related skeletal dysplasia in childhood[J]. Ann Pediatr Endocrinol Metab, 2022, 27(2): 90-97. PMID: 35793999. PMCID: PMC9260370. DOI: 10.6065/apem.2244114.057.
5 代伟倩, 顾学范, 余永国. 中国210例软骨发育不全患儿临床遗传特征分析及生长发育曲线探索[J]. 中华儿科杂志, 2020, 58(6): 461-467. PMID: 32521957. DOI: 10.3760/cma.j.cn112140-20200217-00096.
6 Leiva-Gea A, Martos Lirio MF, Barreda Bonis AC, et al. Achondroplasia: update on diagnosis, follow-up and treatment[J]. An Pediatr (Engl Ed), 2022, 97(6): 423.e1-423.e11. PMID: 36347803. DOI: 10.1016/j.anpede.2022.10.004.
7 McGraw SA, Henne JC, Nutter J, et al. Treatment goals for achondroplasia: a qualitative study with parents and adults[J]. Adv Ther, 2022, 39(7): 3378-3391. PMID: 35672555. PMCID: PMC9239927. DOI: 10.1007/s12325-022-02190-6.
8 Constantinides C, Landis SH, Jarrett J, et al. Quality of life, physical functioning, and psychosocial function among patients with achondroplasia: a targeted literature review[J]. Disabil Rehabil, 2022, 44(21): 6166-6178. PMID: 34403286. DOI: 10.1080/09638288.2021.1963853.
9 Stender M, Pimenta JM, Cheung M, et al. Comprehensive literature review on the prevalence of comorbid conditions in patients with achondroplasia[J]. Bone, 2022, 162: 116472. PMID: 35728791. DOI: 10.1016/j.bone.2022.116472.
10 Onesimo R, Sforza E, Bedeschi MF, et al. How pain affect real life of children and adults with achondroplasia: a systematic review[J]. Eur J Med Genet, 2023, 66(11): 104850. PMID: 37758167. DOI: 10.1016/j.ejmg.2023.104850.
11 Cormier-Daire V, AlSayed M, Alves I, et al. Optimising the diagnosis and referral of achondroplasia in Europe: European Achondroplasia Forum best practice recommendations[J]. Orphanet J Rare Dis, 2022, 17(1): 293. PMID: 35897040. PMCID: PMC9327303. DOI: 10.1186/s13023-022-02442-2.
12 刘明嫦, 马敬. 中国软骨发育不全特征分析及产前诊断方法探讨[J]. 云南医药, 2019, 40(2): 97-100.
13 Kubota T, Adachi M, Kitaoka T, et al. Clinical practice guidelines for achondroplasia[J]. Clin Pediatr Endocrinol, 2020, 29(1): 25-42. PMID: 32029970. PMCID: PMC6958518. DOI: 10.1297/cpe.29.25.
14 中国医师协会医学遗传医师分会, 中华医学会儿科学分会内分泌遗传代谢学组, 中华医学会儿科学分会罕见病学组, 等. 软骨发育不全诊断及治疗专家共识[J]. 中华儿科杂志, 2021, 59(7): 545-550. PMID: 34405635. DOI: 10.3760/cma.j.cn112140-20201229-01142.
15 王瑞芳, 余永国. 软骨发育不全的指南变迁与多学科诊疗建议[J]. 中国实用儿科杂志, 2022, 37(8): 588-595. DOI: 10.19538/j.ek2022080606.
16 Savarirayan R, Rossiter JP, Hoover-Fong JE, et al. Best practice guidelines regarding prenatal evaluation and delivery of patients with skeletal dysplasia[J]. Am J Obstet Gynecol, 2018, 219(6): 545-562. PMID: 30048634. DOI: 10.1016/j.ajog.2018.07.017.
17 Bedeschi MF, Mora S, Antoniazzi F, et al. The clinical management of children with achondroplasia in Italy: results of clinician and parent/caregiver surveys[J]. J Endocrinol Invest, 2024, 47(2): 345-356. PMID: 37466810. DOI: 10.1007/s40618-023-02151-y.
18 Vallin AL, Grévent D, Bessières B, et al. Foetal achondroplasia: prenatal diagnosis, outcome and perspectives[J]. J Gynecol Obstet Hum Reprod, 2024, 54(2): 102891. PMID: 39643117. DOI: 10.1016/j.jogoh.2024.102891.
19 中国医师协会妇产科医师分会母胎医师专业委员会, 中华医学会妇产科学分会产科学组, 中华医学会围产医学分会, 等. 妊娠期应用辐射性影像学检查的专家建议[J] . 中华围产医学杂志, 2020, 23(3): 145-149. DOI: 10.3760/cma.j.cn113903-20200305-00198.
20 中华人民共和国国家卫生健康委员会妇幼健康司. 国家卫生健康委关于印发开展产前筛查技术医疗机构基本标准和开展产前诊断技术医疗机构基本标准的通知: 国卫妇幼函〔2019〕297号[EB/OL]. (2020-01-03)[2024-07-08]. http://www.nhc.gov.cn/fys/s3589/202001/7db164d969474463bba34bebffcc8305.shtml.
21 Vivanti AJ, Costa JM, Rosefort A, et al. Optimal non-invasive diagnosis of fetal achondroplasia combining ultrasonography with circulating cell-free fetal DNA analysis[J]. Ultrasound Obstet Gynecol, 2019, 53(1): 87-94. PMID: 29380944. DOI: 10.1002/uog.19018.
22 Fagen KE, Blask AR, Rubio EI, et al. Achondroplasia in the premature infant: an elusive diagnosis in the neonatal intensive care unit[J]. AJP Rep, 2017, 7(1): e8-e12. PMID: 28210519. PMCID: PMC5310945. DOI: 10.1055/s-0036-1592188.
23 Zhang X, Jiang S, Zhang R, et al. Review of published 467 achondroplasia patients: clinical and mutational spectrum[J]. Orphanet J Rare Dis, 2024, 19(1): 29. PMID: 38281003. PMCID: PMC10822181. DOI: 10.1186/s13023-024-03031-1.
24 Wrobel W, Pach E, Ben-Skowronek I. Advantages and disadvantages of different treatment methods in achondroplasia: a review[J]. Int J Mol Sci, 2021, 22(11): 5573. PMID: 34070375. PMCID: PMC8197470. DOI: 10.3390/ijms22115573.
25 Hoover-Fong J, McGready J, Schulze K, et al. A height-for-age growth reference for children with achondroplasia: expanded applications and comparison with original reference data[J]. Am J Med Genet A, 2017, 173(5): 1226-1230. PMID: 28374958. DOI: 10.1002/ajmg.a.38150.
26 Kanazawa H, Tanaka H, Inoue M, et al. Efficacy of growth hormone therapy for patients with skeletal dysplasia[J]. J Bone Miner Metab, 2003, 21(5): 307-310. PMID: 12928832. DOI: 10.1007/s00774-003-0425-7.
27 Pinto G, Cormier-Daire V, Le Merrer M, et al. Efficacy and safety of growth hormone treatment in children with hypochondroplasia: comparison with an historical cohort[J]. Horm Res Paediatr, 2014, 82(6): 355-363. PMID: 25323764. DOI: 10.1159/000364807.
28 仇艳. 内分泌调节治疗小儿软骨发育不全11例临床分析[J]. 吉林大学学报（医学版）, 2011, 37(4): 694. DOI: 10.13481/j.1671-587x.2011.04.044.
29 Miccoli M, Bertelloni S, Massart F. Height outcome of recombinant human growth hormone treatment in achondroplasia children: a meta-analysis[J]. Horm Res Paediatr, 2016, 86(1): 27-34. PMID: 27355624. DOI: 10.1159/000446958.
30 Horton WA, Hall JG, Hecht JT. Achondroplasia[J]. Lancet, 2007, 370(9582): 162-172. PMID: 17630040. DOI: 10.1016/S0140-6736(07)61090-3.
31 中华医学会儿科学分会内分泌遗传代谢学组, 《中华儿科杂志》编辑委员会. 基因重组人生长激素儿科临床规范应用的建议[J]. 中华儿科杂志, 2013, 51(6): 426-432. PMID: 24120059. DOI: 10.3760/cma.j.issn.0578-1310.2013.06.007.
32 中国人体健康科技促进会生育力保护与保存专业委员会. 特纳综合征中国专家共识（2022年版）[J]. 中国实用妇科与产科杂志, 2022, 38(4): 424-433. DOI: 10.19538/j.fk2022040111.
33 Hertel NT, Ekl?f O, Ivarsson S, et al. Growth hormone treatment in 35 prepubertal children with achondroplasia: a five-year dose-response trial[J]. Acta Paediatr, 2005, 94(10): 1402-1410. PMID: 16299871. DOI: 10.1111/j.1651-2227.2005.tb01811.x.
34 Harada D, Namba N, Hanioka Y, et al. Final adult height in long-term growth hormone-treated achondroplasia patients[J]. Eur J Pediatr, 2017, 176(7): 873-879. PMID: 28501952. PMCID: PMC5486548. DOI: 10.1007/s00431-017-2923-y.
35 王丹丹, 季兴. 基因重组生长激素的合理应用及规范化治疗[J]. 中国合理用药探索, 2023, 20(5): 20-22. DOI: 10.3969/j.issn.2096-3327.2023.05.003.
36 H?gler W, Ward LM. New developments in the management of achondroplasia[J]. Wien Med Wochenschr, 2020, 170(5/6): 104-111. PMID: 32144686. PMCID: PMC7098936. DOI: 10.1007/s10354-020-00741-6.
37 Fafilek B, Bosakova M, Krejci P. Expanding horizons of achondroplasia treatment: current options and future developments[J]. Osteoarthritis Cartilage, 2022, 30(4): 535-544. PMID: 34864168. DOI: 10.1016/j.joca.2021.11.017.
38 Savarirayan R, Tofts L, Irving M, et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial[J]. Lancet, 2020, 396(10252): 684-692. PMID: 32891212. DOI: 10.1016/S0140-6736(20)31541-5.
39 Savarirayan R, Tofts L, Irving M, et al. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study[J]. Genet Med, 2021, 23(12): 2443-2447. PMID: 34341520. PMCID: PMC8327889. DOI: 10.1038/s41436-021-01287-7.
40 Savarirayan R, Wilcox WR, Harmatz P, et al. Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Child Adolesc Health, 2024, 8(1): 40-50. PMID: 37984383. DOI: 10.1016/S2352-4642(23)00265-1.
41 Tofts L, Ireland P, Tate T, et al. Consensus guidelines for the use of vosoritide in children with achondroplasia in Australia[J]. Children (Basel), 2024, 11(7): 789. PMID: 39062238. PMCID: PMC11274906. DOI: 10.3390/children11070789.
42 Savarirayan R, Hoernschemeyer DG, Ljungberg M, et al. Once-weekly TransCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-escalation trial[J]. EClinicalMedicine, 2023, 65: 102258. PMID: 37823031. PMCID: PMC10562841. DOI: 10.1016/j.eclinm.2023.102258.
43 Bat?bay SG, Balc? H?, Bayram S, et al. Quality of life evaluation following limb lengthening surgery in patients with achondroplasia[J]. Indian J Orthop, 2020, 54(Suppl 1): 39-46. PMID: 32952908. PMCID: PMC7474039. DOI: 10.1007/s43465-020-00127-1.
44 Song SH, Kim SE, Agashe MV, et al. Growth disturbance after lengthening of the lower limb and quantitative assessment of physeal closure in skeletally immature patients with achondroplasia[J]. J Bone Joint Surg Br, 2012, 94(4): 556-563. PMID: 22434475. DOI: 10.1302/0301-620X.94B4.28375.
45 Balci H?, Anarat FB, Bayram S, et al. Does the technique of limb lengthening affect physeal growth in patient with achondroplasia? Comparison of the simultaneous and consecutive tibia and femur lengthening with external fixators[J]. J Pediatr Orthop B, 2023, 32(1): 60-65. PMID: 36125888. DOI: 10.1097/BPB.0000000000001011.
46 Hoover-Fong J, Scott CI, Jones MC, et al. Health supervision for people with achondroplasia[J]. Pediatrics, 2020, 145(6): e20201010. PMID: 32457214. DOI: 10.1542/peds.2020-1010.
47 施玉婷, 巩纯秀. 软骨发育不全的诊治研究进展[J]. 世界临床药物, 2020, 41(9): 733-741. DOI: 10.13683/j.wph.2020.09.014.